ADC Manufacturing And The Challenges To Overcome

By Brian Moloney, Director New Products & Innovation

Antibody drug conjugates (ADCs) are a promising alternative for cancer therapy, but their high toxicity presents a lot of challenges. Companies working to scale up and industrial production of ADCs face complications due to the high safety measures needed to guarantee product efficacy and protect the working environment for staff and manufacturers.

This formulation is inspiring further research due to the potential it shows using mAbs in combination with a highly toxic payload drug to easily target cancer cells without potential harm to healthy cells.